Ivonescimab+化疗在高级肺癌与tislelizumab+化疗中的存活率提高,副作用减少。 Ivonescimab plus chemo improved survival in advanced lung cancer vs. tislelizumab plus chemo, with fewer side effects.

试验的第三阶段,HARMONi-6,发现,与tislelizumab和化疗相比,IVONESCIMAB加化学疗法显著改善了晚期状非小细胞肺癌的无进展生存期,PFS的中位数为11. 14个月,而PFS为6. 90个月,进化或死亡风险降低了40%. A Phase III trial, HARMONi-6, found that ivonescimab plus chemotherapy significantly improved progression-free survival in advanced squamous non-small cell lung cancer compared to tislelizumab plus chemotherapy, with a median PFS of 11.14 months versus 6.90 months, a 40% reduction in risk of progression or death. 这种好处在各分组之间是一致的,该药物显示出一种有利的安全特征。 The benefit was consistent across subgroups, and the drug showed a favorable safety profile. 结果在ESMO 2025上发表,并发表在"柳叶刀"杂志上. Results were presented at ESMO 2025 and published in The Lancet.